利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

46 条记录 (耗时 0.076 秒)

    LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION
    31.
    发明申请
    LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION 失效
    作为ABETTA蛋白生产抑制剂的循环成分取代的LACTAMS

    公开(公告)号：US20080103128A1

    公开(公告)日：2008-05-01

    申请号：US11931936

    申请日：2007-10-31

    申请人： Richard Olson

    发明人： Richard Olson

    IPC分类号： A61K31/5513 ,  A61P25/28 ,  A61K31/55 ,  C07D487/00

    CPC分类号： C07D223/16 ,  C07D223/12 ,  C07D223/18 ,  C07D243/12 ,  C07D243/14 ,  C07D243/24 ,  C07D243/26

    摘要： This invention relates to novel lactams having the Formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译： 本发明涉及具有式（I）的新型内酰胺：其药物组合物及其使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工，更具体地，抑制Aβ肽的产生，从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地，本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病，例如阿尔茨海默病和唐氏综合征。

    Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
    32.
    发明申请
    Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines 有权
    用紫杉烷类和13-脱氧蒽环类药物组合进行抗癌治疗

    公开(公告)号：US20070249547A1

    公开(公告)日：2007-10-25

    申请号：US11408000

    申请日：2006-04-21

    申请人： Richard Olson ,  Gerald Walsh

    发明人： Richard Olson ,  Gerald Walsh

    IPC分类号： A61K31/704 ,  A61K31/337

    CPC分类号： A61K31/337 ,  A61K31/704 ,  A61K2300/00

    摘要： A 13-deoxy anthracycline and a taxane can be administered to a patient simultaneously, separately, sequentially, or consecutively to produce a therapeutic anticancer effect with reduced toxicity and side effect profile, compared to the administration of equieffective amounts of either compound alone. A composition or preparation of a 13-deoxy anthracyclines and a taxane for producing a potent anticancer therapeutic effect is also provided.

    摘要翻译： 与单独施用任一化合物的等效量相比，可以同时，分别，依次或连续地向患者施用13-脱氧蒽环类抗生素和紫杉烷类，以产生具有降低的毒性和副作用特征的治疗性抗癌作用。 还提供了用于产生有效的抗癌治疗效果的13-脱氧蒽环类抗生素和紫杉烷的组合物或制剂。

    Succinoylaminobenzodiazepines as inhibitors of Abeta protein production
    35.
    发明申请
    Succinoylaminobenzodiazepines as inhibitors of Abeta protein production 有权
    琥珀酰氨基苯二氮卓类作为Abeta蛋白生产的抑制剂

    公开(公告)号：US20060025407A1

    公开(公告)日：2006-02-02

    申请号：US11230203

    申请日：2005-09-19

    申请人： Richard Olson

    发明人： Richard Olson

    IPC分类号： A61K31/5513

    CPC分类号： C07D223/16 ,  C07D243/12 ,  C07D243/14 ,  C07D243/24 ,  C07D401/04

    摘要： This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译： 本发明涉及具有式（I）的新型内酰胺：其药物组合物及其使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工，更具体地，抑制Aβ肽的产生，从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地，本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病，例如阿尔茨海默病和唐氏综合征。

    Substituted lactams as inhibitors of Abeta protein production
    38.
    发明申请
    Substituted lactams as inhibitors of Abeta protein production 有权
    取代的内酰胺作为Abeta蛋白质生产的抑制剂

    公开(公告)号：US20070173491A1

    公开(公告)日：2007-07-26

    申请号：US11655637

    申请日：2007-01-19

    申请人： Qi Han ,  Hong Liu ,  Richard Olson ,  Michael Yang

    发明人： Qi Han ,  Hong Liu ,  Richard Olson ,  Michael Yang

    IPC分类号： A61K31/55 ,  A61K31/5513 ,  C07D417/02 ,  C07D413/02 ,  C07D403/02

    CPC分类号： C07D401/04 ,  C07D223/12 ,  C07D223/18 ,  C07D243/12 ,  C07D243/24 ,  C07D403/02

    摘要： This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译： 本发明涉及式（I）的新型内酰胺：具有药物和生物影响性质，其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工，更具体地，抑制Aβ肽的产生，从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地，本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病，例如阿尔茨海默病和唐氏综合征。